Multimodality therapy for pancreatic cancer in the U.S.: Utilization, outcomes, and the effect of hospital volume

Cancer

Volumn 110, Issue 6, 2007, Pages 1227-1234

  Bilimoria, Karl Y ^a,b   Bentrem, David J ^a   Ko, Clifford Y ^b,c   Tomlinson, James S ^c   Stewart, Andrew K ^b   Winchester, David P ^b,d   Talamonti, Mark S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b National Cancer Data Base   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Evanston Northwestern Healthcare ^*  (United States)

Author keywords

Chemotherapy; Multimodality therapy; National Cancer Data Base; Pancreatic neoplasms; Radiation therapy; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL;

ACADEMIC MEDICAL CENTERS; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; FEMALE; HOSPITAL BED CAPACITY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PANCREATECTOMY; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RESEARCH DESIGN; SURVIVAL ANALYSIS; UNITED STATES;

EID: 34548801429     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22916     Document Type: Article

References (47)

1. American Cancer Society: Cancer Facts and Figures. Available at URL: http://www.cancer.org/docroot/stt/stt_0.asp Accessed December 15, 2006.
2. Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg. 1995;130:295-299; discussion 299-300.
3. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27:324-329.
4. Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg. 2004;139:718-725; discussion 725-717.
5. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
6. Conlon KC, Klimstra DS, Brennan ME Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-279.
7. Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg. 1993;217:430-435; discussion 435-438.
8. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10-15.
9. Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relationship of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 1995;222:638-645.
10. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447-458.
11. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
12. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
13. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621-633; discussion 633-626.
14. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185: 476-480.
15. Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol. 2004;85:1-3.
16. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S. International Classification of Disease for Oncology. 3rd ed. Geneva: World Health Organization; 2000.
17. Phillips JL, Stewart AK. Facility Oncology Registry Data Standards. Chicago: Commission on Cancer; 2004.
18. Johnson CH, Richards L. Standards of the Commission on Cancer. VolumeII:Registry Operations and Data Standards. Chicago: Commission on Cancer; 1998.
19. Commission on Cancer. Approvals Categories. Available at URL: http://www.facs.org/cancer/coc/categories.html Accessed December 17, 2006.
20. National Comprehensive Cancer Network (NCCN). Available at URL: www.nccn.org Accessed December 15, 1007.
21. United States Department of Agriculture. Urban-Rural Continuum Codes. Washington, DC: United States Department of Agriculture; 2003.
22. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Cox D. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
24. Sener SF, Fremgen A, Menck HR, Winchester DE Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
25. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14:1320-1326.
26. Riall TS, Nealon WH, Goodwin JS, et al. Pancreatic cancer in the general population: improvements in survival over the last decade. J Gastrointest Surg. 2006;10:1212-1223; discussion 1223-1214.
27. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
28. Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA. 1998;280:1747-1751.
29. Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg. 2005;242:540-544; discussion 544-547.
30. Gordon TA, Bowman HM, Tielsch JM, Bass EB, Burleyson GP, Cameron JL. Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann Surg. 1998;228:71-78.
31. Ho V, Heslin MJ. Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg. 2003;237:509-514.
32. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998;228:429-438.
33. Brennan MF. Adjuvant therapy following resection for pancreatic adenocarcinoma. Surg Oncol Clin N Am. 2004;13: 555-566, vii.
34. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85.
35. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293-1300.
36. Bickell NA, Chassin MR. Determining the quality of breast cancer care: do tumor registries measure up? Ann Intern Med. 2000;132:705-710.
37. Cress RD, Zaslavsky AM, West DW, Wolf RE, Felter MC, Ayanian JZ. Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care. 2003;41:1006-1012.
38. Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst. 2002;94:835-844.
39. Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF. Cost analysis of pancreatic carcinoma treatment. Cancer. 2000;89:1917-1924.
40. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002;40(8 suppl):IV-49-54.
41. Chassin MR. Achieving and sustaining improved quality: lessons from New York State and cardiac surgery. Health Aff (Millwood). 2002;21:40-51.
42. Iezzoni L.Risk Adjustment for Measuring Healthcare Outcomes. Volume 3. Chicago: Health Administration Press; 2003.
43. Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs' NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg. 1998;228:491-507.
44. Birkmeyer JD, Warshaw AL, Finlayson SR, Grove MR, Tosteson AN. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery. 1999;126:178-183.
45. Birkmeyer NJ, Goodney PP, Stukel TA, Hillner BE, Birkmeyer JD. Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer. 2005;103:435-441.
46. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
47. Finlayson EV, Goodney PP, Birkmeyer JD. Hospital volume and operative mortality in cancer surgery: a national study. Arch Surg. 2003;138:721-725; discussion 726.